At an extraordinary general meeting of Nanologica AB (publ) on 26 February 2020, a decision was taken to approve the preferential rights issue worth approximately MSEK 55 that the Board of Directors of Nanologica had previously resolved to implement. The intention is for Nanologica to use the issue proceeds to finance the continued production of silica and the development of the company’s drug delivery platform. The company sees good opportunities to build significant value in both its business areas.
The subscription period for the preferential rights issue ended on 26 March 2020 and resulted in the issue being fully subscribed, with 42.0 per cent being subscribed for with exercise of subscription rights and 11.5 per cent without exercise of subscription rights. The remaining shares, corresponding to 46.4 per cent, were subscribed for by the company’s largest shareholder, Thomas Eldered, through Flerie Invest AB, in accordance with the guarantee commitment. Nanologica will thus be provided with MSEK 55.4 before issue expenses.
Erik Penser Bank has acted as the financial advisor and Advokatfirman Lindahl the legal advisor to Nanologica in connection with the preferential rights issue.
Advokatfirman Lindahl’s team consists of Mårten Steen (responsible partner), Emira Peterson and Emelie Carmhagen Wernoff.
